Glossary:
Overall response rate: the percentage of patients who have a complete or partial response to a treatment.
Disease control rate: the percentage of patients who have a complete, partial or stable response to a cancer treatment.
- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
February 20, 2025
Dr. Nataliya Uboha
Dr. Nataliya Uboha
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
Among patients with heavily pretreated patients with KRAS G12C–mutant unresectable or metastatic colorectal cancer, treatment with Krazati (adagrasib) to Erbitux (cetuximab) continued to show meaningful efficacy, according to data from the phase 1/2 KRYSTAL-1 trial, Dr. Nataliya Uboha explained.
At the 2025 ASCO Gastrointestinal Cancers Symposium, Uboha and others shared that at a median follow-up of 20.4 months, the overall response rate was 34% by blinded independent central review and 43% by investigator assessment. Meanwhile, disease control rates were 85% and 86%, respectively.
Uboha is a medical oncologist at UW Health, as well as an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. In an interview with CURE, she sat down to discuss the KRYSTAL-1 study which evaluated patients with KRAS G12C-mutated metastatic colorectal cancer and highlighted what makes Krazati combined with Erbitux a potential treatment option for these patients.
Transcript:
We are seeing a very good signal of activity with these two drugs in patients with colorectal cancer with this mutation. Initially Krazati was developed primarily for patients with lung cancer; however, we see mutations in the KRAS gene with much more frequently in lung cancer. Subsequently, we were studying Krazati in patients with gastrointestinal cancers, in particular colorectal cancer. We have found out that when we combine this drug with an anti-EGFR drug, we see much better efficacy, and much better activity.
What we have learned from the KRYSTAL-1 trial is that patients with colorectal cancer who have had chemotherapy in the past and whose cancer continue to grow and as well as carry this mutation have a good chance of responding to this treatment. This is a treatment that does not include chemotherapy, so it is relatively well tolerated, and it is quite active in patients who have tumors with this particular mutation.
Transcript has been edited for clarity and conciseness.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content:
